Alaunos Therapeutics received a deficiency notice from Nasdaq on April 9, 2026. The company failed to meet the minimum stockholders' equity requirement of $2,500,000. The 2025 Form 10-K reported stockholders' equity of $2,153,000. The company does not currently meet alternative listing standards, including market value or net income requirements. A compliance plan must be submitted to Nasdaq by May 26, 2026.